// App-Quantinova.ai

: EXTH-25. DIANHYDROGALACTITOL (VAL-083) REDUCES GLIOBLASTOMA TUMOR GROWTH IN VIVO, UPON BEVACIZUMAB-INDUCED HYPOXIA

Researchers

Presenter

  • Anna Golebiewska

Principal Investigators

  • Anais Oudin

  • Anne Steino

  • Simone Niclou

  • Dennis Brown

  • Jeffrey Bacha

Medical Centers

  • NorLux Neuro-Oncology Laboratory, Luxembourg Institute of Health, Luxembourg, Luxembourg

  • Del Mar Pharmaceuticals, Vancouver, BC, Canada

  • DelMar Pharmaceuticals, San Francisco, CA.

Locations

  • Luxembourg

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Solute Carrier Family 2 Member 3

Drug/Treatment

  • Dianhydrogalactitol

  • Temozolomide

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved